The Co-occurrence of Chronic Hepatitis B and Fibrosis Is Associated With a Decrease in Hepatic Global DNA Methylation Levels in Patients With Non-alcoholic Fatty Liver Disease

Li, Fangyuan; Ou, Qian; Lai, Zhi-Wei; Pu, Liuzhen; Chen, XingYi; Wang, Lirong; Sun, Liuqiao; Liang, XiaoPing; Wang, Yaoyao; Xu, Hang; Wei, Jintao; Wu, Feng; Zhu, Huilian; Wang, Lijun

doi:10.3389/fgene.2021.671552

Cited by 3 publications

(3 citation statements)

References 39 publications

(66 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hepatitis B virus (HBV) is one of the most serious threats to human life, health, and safety. According to the statistics of relevant institutions, there are about 2 billion patients who have been infected with HBV worldwide, of which about 400 million infected patients develop Chronic Hepatitis B (CHB) [ 1 ]. While China, as one of the globally recognized populous countries, has up to 20 million CHB patients, accounting for approximately 5% of CHB patients worldwide [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Peginterferon α-2a and Entecavir Tenofovir in the Treatment of Chronic Hepatitis B Genotype C

2022

Contrast Media & Molecular Imaging

View full text Add to dashboard Cite

This article discusses the clinical value of Pegylated Interferon (PEG-IFN) α-2a combined with entecavir or tenofovir in the treatment of Chronic Hepatitis B (CHB) genotype C patients. 78 patients with CHB genotype C were divided into three groups: control group, entecavir group, and tenofovir group according to different treatment methods. The efficacy and adverse reaction (AR) of the three groups are observed during 12 months of treatment and after drug withdrawal, and the clinical efficacy and safety of the three treatment methods are evaluated. The experimental results show that the sustained response rate (RR) in the tenofovir and entecavir groups is higher than that in the controls. The incidence of total AR in the tenofovir group is significantly higher than that in the control and entecavir groups. PEG-IFN α-2a and entecavir or tenofovir are more effective, and tenofovir has an antiviral effect.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Peginterferon α-2a and Entecavir Tenofovir in the Treatment of Chronic Hepatitis B Genotype C

2022

Contrast Media & Molecular Imaging

View full text Add to dashboard Cite

show abstract

“…A recent study found that patients with concurrent NAFLD and CHB exhibited lower levels of global DNA methylation than patients with NAFLD alone. The concurrence of CHB and liver fibrosis in NAFLD patients was associated with a decrease in the global DNA methylation levels [87] . NAFLD-related cumulative fat deposition, oxidative stress, and inflammatory responses may produce a pro-fibrotic and pro-cancer environment in the liver and further accelerate the development of cirrhosis and HCC.…”

Section: Progression and Outcomes Of Chb With Nafldmentioning

confidence: 99%

“…The concurrence of CHB and liver fibrosis in NAFLD patients was associated with a decrease in the global DNA methylation levels. [ 87 ] NAFLD-related cumulative fat deposition, oxidative stress, and inflammatory responses may produce a pro-fibrotic and pro-cancer environment in the liver and further accelerate the development of cirrhosis and HCC. However, the disease progression is influenced by various confounding factors, and the interaction between HBV and metabolic homeostasis in the progression of liver disease requires further study.…”

Section: Progression and Outcomes Of Chb With Nafldmentioning

confidence: 99%

Clinical impact and mechanisms of hepatitis B virus infection concurrent with non-alcoholic fatty liver disease

Tong

Song

Yin

et al. 2022

Chinese Medical Journal

View full text Add to dashboard Cite

Chronic hepatitis B (CHB) virus infection is an important threat to global health despite the administration of vaccines and the use of antiviral treatments. In recent years, as the prevalence of obesity and metabolic syndrome has increased, non-alcoholic fatty liver disease (NAFLD) in patients with CHB has become more common. Both diseases can lead to liver fibrosis and even hepatocellular carcinoma, but the risk of dual etiology, outcome, and CHB combined with NAFLD is not fully elucidated. In this review, we assess the overlapping prevalence of NAFLD and CHB, summarize recent studies of clinical and basic research related to potential interactions, and evaluate the progressive changes of treatments for CHB patients with NAFLD. This review increases the understanding of the relationship and mechanisms of interaction between steatosis and hepatitis B virus infection, and it provides new strategies for the future clinical management and treatment of CHB combined with NAFLD.

show abstract

Metabolic Dysfunction-Associated Fatty Liver Disease and Chronic Viral Hepatitis: The Interlink

Fernandez,

Alkhalifah,

Afsar

et al. 2024

Pathogens

View full text Add to dashboard Cite

Metabolic dysfunction-associated fatty liver disease (MAFLD) has now affected nearly one-third of the global population and has become the number one cause of chronic liver disease in the world because of the obesity pandemic. Chronic hepatitis resulting from hepatitis B virus (HBV) and hepatitis C virus (HCV) remain significant challenges to liver health even in the 21st century. The co-existence of MAFLD and chronic viral hepatitis can markedly alter the disease course of individual diseases and can complicate the management of each of these disorders. A thorough understanding of the pathobiological interactions between MAFLD and these two chronic viral infections is crucial for appropriately managing these patients. In this comprehensive clinical review, we discuss the various mechanisms of chronic viral hepatitis-mediated metabolic dysfunction and the impact of MAFLD on the progression of liver disease.

show abstract

The Co-occurrence of Chronic Hepatitis B and Fibrosis Is Associated With a Decrease in Hepatic Global DNA Methylation Levels in Patients With Non-alcoholic Fatty Liver Disease

Cited by 3 publications

References 39 publications

Efficacy and Safety of Peginterferon α-2a and Entecavir Tenofovir in the Treatment of Chronic Hepatitis B Genotype C

Efficacy and Safety of Peginterferon α-2a and Entecavir Tenofovir in the Treatment of Chronic Hepatitis B Genotype C

Clinical impact and mechanisms of hepatitis B virus infection concurrent with non-alcoholic fatty liver disease

Metabolic Dysfunction-Associated Fatty Liver Disease and Chronic Viral Hepatitis: The Interlink

Contact Info

Product

Resources

About